PixarBio Corporation

PXRB

US72582G1094

Pharmaceuticals

Delayed OTC Markets Other stock markets 03:17:43 2023-06-27 pm EDT			5-day change	1st Jan Change
0.000001 ^USD	-.--%		-.--%	-.--%

2018	PixarBio Corporation Clarifies Pathways to FDA Approval for NR14 to Treat “Trigeminal Neuralgia” and Post-Surgical Pain	CI
2018	Pixarbio Corporation Announces the Removal of Katrin Holzhaus as Chief Administration Officer and Corporate Secretary of the Company	CI

PixarBio Corporation announced that it has received $0.21 million in funding

May 01, 2017

On May 2, 2017, PixarBio Corporation (OTCPK:PXRB) closed the transaction. The company has received $211,100 in from five investors.

Latest news about PixarBio Corporation

PixarBio Corporation Clarifies Pathways to FDA Approval for NR14 to Treat “Trigeminal Neuralgia” and Post-Surgical Pain	18-02-27	CI
Pixarbio Corporation Announces the Removal of Katrin Holzhaus as Chief Administration Officer and Corporate Secretary of the Company	18-02-15	CI
PixarBio Corporation announced that it has received $0.411258 million in funding	18-02-11	CI
PixarBio Corporation Announces Change of Directors	17-12-28	CI
PixarBio Corp Announces Resignation of Derek Bridges Member of Board of Directors	17-12-22	CI
PixarBio Corporation announced a financing transaction	17-11-12	CI
PixarBio Corporation announced that it has received $0.0885 million in funding	17-06-29	CI
PixarBio Corporation announced a financing transaction	17-06-14	CI
PixarBio Corporation announced that it has received $0.21 million in funding	17-05-01	CI
PixarBio Corporation announced a financing transaction	17-04-16	CI
Pixarbio Corporation Announces Termination of Robert S. Langer as a Member of Scientific Advisory Board	17-03-10	CI
PixarBio Corporation Announces Management Changes	17-02-09	CI
PixarBio Corporation cancelled the acquisition of InVivo Therapeutics Holdings Corp..	17-01-22	CI
PixarBio Corporation announced that it has received $0.3 million in funding	17-01-22	CI
Henry Sargent acquired Buddhi Mat LLC from PixarBio Corporation.	17-01-04	CI
PixarBio Corporation made a bid to acquire InVivo Therapeutics Holdings Corp. for $77 million.	17-01-02	CI
PixarBio Corporation Establishes the JP Reynolds Research Center in Woburn, MA	16-12-21	CI
PixarBio Corporation Appoints Steve Chartier as Chief Operating Officer	16-12-20	CI
PixarBio Corporation Appoints Barry Belfer as Senior Vice President of Finance	16-11-07	CI
PixarBio Corporation Auditor Raises 'Going Concern' Doubt	16-11-03	CI
BMP Holdings Inc. completed the acquisition of BMP Holdings Inc. in a reverse merger transaction.	16-10-29	CI
PixarBio Corporation announced that it has received $7.19 million in funding	16-10-29	CI
Pixarbio Corporation Promotes Ken Stromsland to Vice-President, CIO External Communications	16-10-20	CI
BMP Holdings Inc. agreed to acquire BMP Holdings Inc. in a reverse merger transaction.	16-08-23	CI
BMP Holdings Inc. announced that it has received $0.22 million in funding from PixarBio Corporation	16-08-18	CI

PixarBio Corporation is a specialty pharmaceutical company that is focused on the pre-clinical and commercial development of novel neurological drug delivery systems for post-operative pain. The Companyâs lead product platform, NeuroRelease, is a novel biodegradable microparticle delivery system for the delivery of non-opiate prescription paid drugs. NeuroRelease offers sustained therapeutic pre-clinical release over time of a non-opiate drug for post-operative, acute, and chronic pain in pre-clinical models involving rodents and pigs. NeuroRelease treats multiple conditions, including pain, Parkinsonâs disease, epilepsy, and spinal cord injury. NeuroRelease is biodegradable, and it is non-toxic so it can be re-injected to extend treatment timelines. Its Injectable NeuroScaffold is a platform to advance from acute neuro-protective spinal cord injury treatment to a regeneration treatment for chronic spinal cord injury.

Sector

Pharmaceuticals

More about the company

Sector Generic Pharmaceuticals

	1st Jan change	Capi.
PIXARBIO CORPORATION	-.--%	81
SUN PHARMACEUTICAL INDUSTRIES LTD.	+19.27%	43.75B
OTSUKA HOLDINGS CO., LTD.	+27.47%	22.06B
SANDOZ GROUP AG	+15.37%	14.46B
CIPLA LIMITED	+12.33%	13.62B
ZYDUS LIFESCIENCES LIMITED	+38.36%	11.61B
ONO PHARMACEUTICAL CO., LTD.	-9.54%	6.9B
THE MEDICINES COMPANY	-0.05%	6.79B
STADA ARZNEIMITTEL	-8.87%	5.73B
ASPEN PHARMACARE HOLDINGS LIMITED	+9.64%	5.32B

Generic Pharmaceuticals